Who is sponsoring NCT04610372?

NCT04610372 is sponsored by British Columbia Cancer Agency.

What drugs are being tested in NCT04610372?

Interventions in NCT04610372: Hypofractionated external beam radiotherapy, High dose rate brachytherapy, Permanent seed implant, Stereotactic body radiotherapy.

What condition does NCT04610372 study?

NCT04610372 studies Oligometastatic Prostate Cancer.

Is NCT04610372 still recruiting?

NCT04610372 is currently recruiting now. Last updated 2 February 2026.

Last reviewed 2026-02-02 · How we verify

NCT04610372: PROMPT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

5500/20 vs. SABR or Brachytherapy for PRimary OligoMetastatic Prostate Cancer Treatment (PROMPT)

Recruiting now NA Last updated 2 February 2026

What this trial tests

NA trial testing Hypofractionated external beam radiotherapy in Oligometastatic Prostate Cancer in 168 participants. Currently enrolling.

Timeline

12 July 2021

Primary endpoint
30 June 2030

30 June 2033

Quick facts

Lead sponsor	British Columbia Cancer Agency
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	168
Start date	12 July 2021
Primary completion	30 June 2030
Estimated completion	30 June 2033
Sites	4 locations across Canada

Drugs / interventions tested

Hypofractionated external beam radiotherapy
High dose rate brachytherapy
Permanent seed implant
Stereotactic body radiotherapy

Conditions studied

Oligometastatic Prostate Cancer — all drugs for Oligometastatic Prostate Cancer →

Sponsor

British Columbia Cancer Agency

Who can join

18 and older, male only, with Oligometastatic Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

We will investigate whether ultrahypofractionation using stereotactic ablative radiotherapy (SABR) or brachytherapy is as well-tolerated as moderately hypofractionated external beam radiotherapy (EBRT) for treating the prostate in patients with oligometastatic prostate cancer. Secondary aims include assessment of progression-free survival (PFS) and overall survival (OS) as well as cost-effectiveness. We hypothesize that ultrahypofractionation will maintain favorable toxicity profiles and quality of life while achieving comparable or better efficacy, thereby providing a convenient and cost-effective alternative to moderately hypofractionated EBRT.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Radioactive Iodine-125 in Tumor Therapy: Advances and Future Directions.
Wei S, Li C, Li M, Xiong Y, et al · · 2021 · cited 38× · PMID 34660280 · DOI 10.3389/fonc.2021.717180
Surgery, radiotherapy and endocrine therapy for oligometastatic prostate cancer efficacy: a systematic review and network meta-analysis.
Ying W, Ding Z, He Y, Wang J, et al · · 2025 · cited 3× · PMID 40900758 · DOI 10.7717/peerj.19819
A Personalized Approach for Oligometastatic Prostate Cancer: Current Understanding and Future Directions.
Alerasool P, Zhou S, Miller E, Anker J, et al · · 2025 · cited 1× · PMID 39796774 · DOI 10.3390/cancers17010147

Verify or expand the search:

Other recruiting trials for Oligometastatic Prostate Cancer

Currently open trials in the same condition.

NCT07015138 — Comprehensive Versus Primary Tumor Radiotherapy in Oligometastatic Prostate Cancer · NA · recruiting
NCT06387056 — Genomic Biomarker-guided Neoadjuvant Therapy for Prostate Cancer (SEGNO) · Phase 2 · recruiting
NCT06972511 — Maximal Tumor Eradication for Oligometastatic Prostate Cancer · Phase 2, PHASE3 · recruiting
NCT06060652 — Prostate Oligometastatic Cancer Management Driven by Disease Biology et/or Immunoactivity (PROMETEO) · recruiting

Other British Columbia Cancer Agency trials

Trials by the same sponsor.

NCT07295171 — HELP Study - Towards High Throughput and Efficient Long-axial PET With Oral [18F]FDG · NA · recruiting
NCT07291895 — High Dose Radiotherapy for Palliation (Hi-D) · NA · not yet recruiting
NCT06918951 — Stereotactic Radiotherapy Versus Palliative Conventional Radiotherapy for Oligoprogressive Metastatic Cancers · NA · recruiting
NCT07210749 — Radiotherapy 12Gy in 6 Fractions For Orbital Lymphoma · NA · not yet recruiting
NCT06835725 — Phase II Randomized Trial of 2 Versus 5 Fraction Prostate Stereotactic Ablative Radiotherapy for Intermediate Risk Prost · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04610372 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by British Columbia Cancer Agency
Last refreshed: 2 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04610372.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing